<DOC>
	<DOCNO>NCT00355030</DOCNO>
	<brief_summary>The present randomized trial initially intend study benefit combine treatment growth hormone ( GH ) gonadotropin-releasing hormone ( GnRH ) agonist pubertal child idiopathic short stature . However , treatment stop January 2012 request French drug agency . Therefore , protocol amendment divide study two study period . Study Period 1 involved combine treatment somatropin leuprorelin treatment somatropin alone . Participants France participate Period 1 study ask participate long term safety follow define Period 2 study . Participants Netherlands offer participation Genetics Neuroendocrinology Short Stature International Study ( GeNeSIS , clinicaltrials.gov Identifier : NCT01088412 ) long term safety follow independent study .</brief_summary>
	<brief_title>Somatropin + Leuprorelin v Somatropin Alone Pubertal Children With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<criteria>male female child ISS age great equal 8 year less equal 12 year 3 month girl great equal 9 year less equal 14 year 3 month boy bone age less equal 12.0 year girls less equal 14.0 year boys base central reading Xray leave hand wrist Pubertal stage B2 B3 girl base Tanner method Pubertal stage G2 G3 boy base Tanner method Growth hormone deficiency ( GHD ) Insulinlike growth factorI level great 3 SDS Chromosomal abnormality diagnose locally karyotype . For girl , karyotype eliminate Turner syndrome , mandatory Small gestational age ( SGA ) Has reach menarche ( first menstrual period ) Have significant concomitant disease likely interfere growth study , know contraindication Growth Hormone treatment</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>171 Months</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>